LenioBio

Dusseldorf, Germany Founded: 2016 • Age: 10 yrs
Kits for cell-free eukaryotic protein expression are provided.
Request Access

About LenioBio

LenioBio is a company based in Dusseldorf (Germany) founded in 2016 by Remberto Martis and Hakon Birgisson.. LenioBio has raised $13.01 million across 7 funding rounds from investors including EIT Food, European Union and Eureka Network. The company has 18 employees as of December 31, 2020. LenioBio offers products and services including ALiCE® Products, ALiCE® as a Service, and ALiCE® for High-Throughput Expression. LenioBio operates in a competitive market with competitors including PrognomiQ, PreOmics, Vivostat, ACRO Biosystems and List Biological Laboratories, among others.

  • Headquarter Dusseldorf, Germany
  • Employees 18 as on 31 Dec, 2020
  • Founders Remberto Martis, Hakon Birgisson
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Leniobio Gmbh
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $13.01 M (USD)

    in 7 rounds

  • Latest Funding Round
    $4.33 M (USD), Grant

    Jul 23, 2025

  • Investors
    EIT Food

    & 5 more

  • Employee Count
    18

    as on Dec 31, 2020

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of LenioBio

LenioBio offers a comprehensive portfolio of products and services, including ALiCE® Products, ALiCE® as a Service, and ALiCE® for High-Throughput Expression. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Enables rapid and scalable protein production for research.

Offers expert services for challenging protein targets.

Facilitates efficient protein expression in high-throughput setups.

People of LenioBio
Headcount 10-50
Employee Profiles 17
Employee Profiles
People
Alexander Dahlmanns, LL.M.
General Counsel
People
Robin Roentgen
Head Of Technical Development
People
Maja Lieven (née Rennig)
Team Lead Production
People
Charles Williams
Lead Strategic Projects

Unlock access to complete

Funding Insights of LenioBio

LenioBio has successfully raised a total of $13.01M across 7 strategic funding rounds. The most recent funding activity was a Grant round of $4.33 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 7
  • Last Round Grant — $4.3M
  • First Round

    (23 Aug 2019)

  • Investors Count 6
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2025 Amount Grant - LenioBio Valuation

investors

Sep, 2023 Amount Grant - LenioBio Valuation

investors

May, 2022 Amount Grant - LenioBio Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in LenioBio

LenioBio has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include EIT Food, European Union and Eureka Network. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Government agency and accelerator focusing on innovative startups and SMEs
Founded Year Domain Location
Early-stage tech companies are invested in by Bridford Group.
Founded Year Domain Location
Food safety testing services are provided by EIT Food.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by LenioBio

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - LenioBio

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Leniobio Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of LenioBio

LenioBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PrognomiQ, PreOmics, Vivostat, ACRO Biosystems and List Biological Laboratories, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Developer of tests for the detection and treatment of cancer and other diseases
domain founded_year HQ Location
Reagents and instruments for proteomics research are supplied by PreOmics.
domain founded_year HQ Location
On-site fibrin sealant preparation systems are developed and provided.
domain founded_year HQ Location
Recombinant proteins are manufactured to support cancer immunotherapy efforts.
domain founded_year HQ Location
Specializes in the production of research reagents
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Leniobio

Frequently Asked Questions about LenioBio

When was LenioBio founded?

LenioBio was founded in 2016 and raised its 1st funding round 3 years after it was founded.

Where is LenioBio located?

LenioBio is headquartered in Dusseldorf, Germany. It is registered at Dusseldorf, North Rhine-westphalia, Germany.

Who is the current CEO of LenioBio?

Remberto Martis is the current CEO of LenioBio. They have also founded this company.

Is LenioBio a funded company?

LenioBio is a funded company, having raised a total of $13.01M across 7 funding rounds to date. The company's 1st funding round was a Grant of $2.9M, raised on Aug 23, 2019.

How many employees does LenioBio have?

As of Dec 31, 2020, the latest employee count at LenioBio is 18.

What does LenioBio do?

LenioBio was founded in 2016 in Dusseldorf, Germany, and operates in the biotechnology sector. Cell-free protein expression kits are developed and supplied, with the ALiCE platform serving as the primary eukaryotic system for handling difficult-to-express proteins. Active energy regeneration is incorporated, along with essential components for protein folding, disulfide bonding, and glycosylation, supporting discovery, development, and production processes.

Who are the top competitors of LenioBio?

LenioBio's top competitors include PrognomiQ, Vivostat and PreOmics.

What products or services does LenioBio offer?

LenioBio offers ALiCE® Products, ALiCE® as a Service, and ALiCE® for High-Throughput Expression.

Who are LenioBio's investors?

LenioBio has 6 investors. Key investors include EIT Food, European Union, Eureka Network, EIC Fund, and Bridford Group.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available